Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FQST4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of STELARA 90 mg/ml syringes. The contract, designated as delivery order 4570029232, is structured as a firm fixed-price arrangement with an ultimate completion date of December 3, 2025. No set-aside designation was utilized for this award, indicating the contractor competed in unrestricted procurement. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the DLA's $30.3 billion PPV-G GEN V acquisition strategy, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036. The IDC authorizes the company to deliver comprehensive pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables, to support the Department of Defense's medical supply needs globally. As a GSA-registered small business since 2001, DMS Pharmaceutical Group has demonstrated substantial performance across multiple delivery orders for the DLA's Medical Supply Chain division, positioning it as a qualified supplier for recurring pharmaceutical requirements across military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FQST4?
SPE2DR26FQST4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 10, 2025.
How much is contract SPE2DR26FQST4 worth?
The government has obligated $16,584 on SPE2DR26FQST4.
Is contract SPE2DR26FQST4 an order under another contract?
Yes. SPE2DR26FQST4 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQST4 competed?
The extent of competition for SPE2DR26FQST4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award